Gagliardi, Geoffroy Houot, Marion Cacciamani, Federica Habert, Marie-Odile Dubois, Bruno Epelbaum, Stéphane Audrain, C. Auffret, A. Bakardjian, H. Baldacci, F.
...
Published in
Alzheimer's Research & Therapy
BackgroundLack of awareness of cognitive decline (ACD) has been described at the preclinical and prodromal stages of Alzheimer’s disease (AD). In this study, we introduced a meta-memory ratio (MMR) and explored how it is associated with neuroimaging AD biomarkers in asymptomatic individuals at risk for AD.MethodFour hundred forty-eight cognitively ...
Wang, Chunyue Cai, Xueying Wang, Ruochen Zhai, Siyu Zhang, Yongfeng Hu, Wenji Zhang, Yizhi Wang, Di
Published in
Journal of Neuroinflammation
BackgroundEndoplasmic reticulum (ER) stress is involved in the progression of Alzheimer’s disease (AD). Verbascoside (VB), an active phenylethanoid glycoside that was first isolated from Verbascum sinuatum (the wavyleaf mullein), possesses anti-inflammatory, antioxidative, and anti-apoptotic effects. The purpose of this study was to elucidate the b...
De Mena, Lorena Smith, Michael A. Martin, Jason Dunton, Katie L. Ceballos-Diaz, Carolina Jansen-West, Karen R. Cruz, Pedro E. Dillon, Kristy D. Rincon-Limas, Diego E. Golde, Todd E.
...
Published in
Alzheimer's Research & Therapy
BackgroundSelf-assembly of the amyloid-β (Aβ) peptide into aggregates, from small oligomers to amyloid fibrils, is fundamentally linked with Alzheimer’s disease (AD). However, it is clear that not all forms of Aβ are equally harmful and that linking a specific aggregate to toxicity also depends on the assays and model systems used (Haass et al., J ...
Sannemann, Lena Schild, Ann-Katrin Altenstein, Slawek Bartels, Claudia Brosseron, Frederic Buerger, Katharina Cosma, Nicoleta Carmen Fliessbach, Klaus Freiesleben, Silka Dawn Glanz, Wenzel
...
Published in
Alzheimer's Research & Therapy
BackgroundEarly identification of individuals at risk of dementia is mandatory to implement prevention strategies and design clinical trials that target early disease stages. Subjective cognitive decline (SCD) and neuropsychiatric symptoms (NPS) have been proposed as potential markers for early manifestation of Alzheimer’s disease (AD). We aimed to...
Hampel, Harald Lista, Simone Vanmechelen, Eugeen Zetterberg, Henrik Giorgi, Filippo Sean Galgani, Alessandro Blennow, Kaj Caraci, Filippo Das, Brati Yan, Riqiang
...
Published in
Alzheimer's Research & Therapy
β-Secretase1 (BACE1) protein concentrations and rates of enzyme activity, analyzed in human bodily fluids, are promising candidate biological markers for guidance in clinical trials investigating BACE1 inhibitors to halt or delay the dysregulation of the amyloid-β pathway in Alzheimer’s disease (AD). A robust body of evidence demonstrates an associ...
Kong, Fan’ge Jiang, Xue Wang, Ruochen Zhai, Siyu Zhang, Yizhi Wang, Di
Published in
Journal of Neuroinflammation
BackgroundNeuroinflammation is a principal element in Alzheimer’s disease (AD) pathogenesis, so anti-inflammation may be a promising therapeutic strategy. Forsythoside B (FTS•B), a phenylethanoid glycoside isolated from Forsythiae fructus, has been reported to exert anti-inflammatory effects. However, no studies have reported whether the anti-infla...
Ding, Bo Lin, Chengheng Liu, Qian He, Yingying Ruganzu, John Bosco Jin, Hui Peng, Xiaoqian Ji, Shengfeng Ma, Yanbing Yang, Weina
...
Published in
Journal of Neuroinflammation
BackgroundGlial activation and neuroinflammation play a crucial role in the pathogenesis and development of Alzheimer’s disease (AD). The receptor for advanced glycation end products (RAGE)-mediated signaling pathway is related to amyloid beta (Aβ)-induced neuroinflammation. This study aimed to investigate the neuroprotective effects of tanshinone ...
Ballard, Clive Kales, Helen C. Lyketsos, Constantine Aarsland, Dag Creese, Byron Mills, Roger Williams, Hilde Sweet, Robert A.
Published in
Current Neurology and Neuroscience Reports
Purpose of ReviewTo review the incidence, treatment and genetics of psychosis in people with mild cognitive impairment (MCI) and Alzheimer’s disease (AD).Recent FindingsPsychosis in Alzheimer’s disease (AD) has an incidence of ~ 10% per year. There is limited evidence regarding psychological interventions. Pharmacological management has focused on ...
Desai, Madhav Nutalapati, Venkat Srinivasan, Sachin Fathallah, Jihan Dasari, Chandra Chandrasekhar, Viveksandeep Thoguluva Mohammad, Bilal Kohli, Divyanshoo Vaezi, Michael Katz, Philip O
...
Published in
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
Published studies have reported variable results on the association between duration of proton pump inhibitor (PPI) use and the risk of dementia. An extensive literature search was performed in PubMed, Embase, Google Scholar, and Cochrane for studies examining the risk of cognitive decline and dementia among PPI users versus non-PPI users in prospe...
Vagaitseva, K. V. Bocharova, A. V. Kolesnikova, E. A. Markova, V. V. Makeeva, O. A. Minaycheva, L. I. Zhukova, I. A. Zhukova, N. G. Stepanov, V. A.
Published in
Russian Journal of Genetics
AbstractHaplotype associations of 894 DNA samples of elderly people from the Russian population of Tomsk were analyzed using 49 SNPs (single nucleotide polymorphisms). As the analyzed markers, SNPs were selected that showed an association with Alzheimer’s disease or variability of cognitive abilities in genome-wide association studies. As a result ...
